mylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and the Sean M. Healey & AMG Center for ALS at Mass General today announced that AMX0035 demonstrated a significant treatment benefit for people with ALS in the CENTAUR study.
Highlights from the meeting included a robust discussion moderated by Dr. Robert Brown with guest speakers Drs. Jean-Pierre Julien, from Laval Universities Department of Psychiatry and Neuroscience, Saud Sadiq, Director and Chief Research Scientist from Tisch MS Research Center of New York and Laura Paulsen, from EnClear Therapies, who spoke on the role of CSF toxicity in ALS pathophysiology.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) awarded the inaugural annual Healey Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS) to the team that brought to trial the first antisense oligonucleotide (ASO) therapy for ALS. Team members include researchers from academia and industry.
Treatment with an anti-inflammatory drug delayed the onset of disease in a mouse model of ALS.
Congratulations to Merit Cudkowicz, MD, MSc, Director of the Sean M. Healey and AMG Center for ALS and Chief of Neurology at Mass General, who presented “A Powerful Promise,” a keynote speech at Accelerating Transformation, the 2019 Press Ganey National Client & Executive Leadership Conference in Orlando, Florida on Tuesday, November 18th.
Thank you to ALS ONE for the generous donation to the Healey Center for ALS! These funds will help us achieve our mission to boldly accelerate the development of effective treatments for ALS, through both lab-based and clinical research.
Friends and family of Healey Center for ALS patient Kathleen McCarron fielded a fundraising team for the Bourbon Chase Ragnar Race.
Members of the Northeast Amyotrophic Lateral Sclerosis Consortium assembled at the Opal Sands Resort, in Clearwater, Florida on October 2nd through October 4th for their 18th Annual Scientific Symposium.
A team from sALSa for a Cure joined the ALSA Walk to Defeat ALS in Westport, CT on October 19 and supported team member Kristen Vaughan in the 2019 New York City Marathon on November 3, both to raise money for ALS research at Mass General.
Two hundred people attended the “Olson it About Time to Cure ALS” Corn Hole Tournament on August 25th in honor of their friend, George Olson, a nationally recognized chemical engineer and former football player at Northeastern University who was diagnosed with ALS at the age of 54. Friends, family and many of George’s old football teammates from college came for the celebratory event.
Research at Massachusetts General Hospital integrates the full spectrum of "bench to bedside" discovery. Laboratory scientists work collaboratively with clinicians to make discoveries and turn them into treatments, diagnostics and devices that improve our quality of life.
